GLP-1 Drugs Linked to Lower Risk of TED

GLP-1 drugs produce substantial weight loss and improve glycemic control, factors that indirectly reduce inflammatory drive. The findings of this recent study point to a potential protective role for GLP-1 drug signaling in modulating orbital inflammation. Photo: Andrew Gurwood, OD. Click image to enlarge. Given that immune system activation can trigger or exacerbate thyroid eye disease (TED), the effects of various medications on autoimmune processes are of clinical interest. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications widely used for type 2 diabetes and obesity. It remains unclear whether their use in a susceptible population, such as patients with both diabetes and underlying thyroid disease, might influence the risk of developing TED.A recent study published in Ophthalmic Plastic and Reconstructive Surgery analyzed new-onset TED outcomes in two large, propensity-matched cohorts of patients with thyroid disease. GLP-1 drug use was associated with a reduced risk of TED diagnoses, surgeries and systemic steroid use compared to other glucose-lowering medications. These findings suggest a potential protective role for GLP-1 signaling in modulating orbital inflammation, though prospective trials are required for confirmation.“This protective association remained consistent across multiple time points and for various clinical outcomes,” the study authors noted in their paper. “Specifically, GLP-1 use was associated with an 18% lower risk of a composite TED-related diagnosis at one year and a 10% lower risk at three years.”This retrospective, population-based cohort study used the TriNetX US Collaborative Network to identify patients with thyroid disease initiating a GLP-1 drug or a non-GLP-1 active control medication. After 1:1 propensity score matching, two balanced cohorts of 173,618 patients each were analyzed.At one year, the risk of a composite TED-related diagnosis was 0.77% in the GLP-1 group vs. 0.94% in the control group (hazard ratio; HR: 0.82). This protective association persisted at two years, with a risk of 1.15% in the GLP-1 group compared to 1.39% in the control group (HR: 0.86). At three years, the incidence was 1.40% vs. 1.68% (HR: 0.90). The refined TED outcome, which focuses on pathognomonic manifestations, followed the same trend, showing a protective effect at all time points, including a one-year risk of 0.42% in the GLP-1 group compared to 0.53% in the control group (HR 0.79).Marked reductions were observed for TED-related surgical interventions (one-year HR: 0.42; three-year HR: 0.54) and systemic steroid use. Subgroup analyses of patients with hyperthyroidism and individual agents demonstrated consistent protective associations.“Our clinical observation of a reduced risk for TED-related interventions suggests that the therapeutic application of GLP-1RAs may influence the inflammatory sequelae of thyroid autoimmunity differently than genetic predisposition alone,” the researchers wrote. “This highlights the need for further research to distinguish between the risk of developing an autoimmune phenotype and the risk of progressing to severe clinical manifestations like TED.”While the research team’s findings suggest a protective association between GLP-1 drug therapy and TED, the underlying biological pathways remain speculative. The potential immunomodulatory effects discussed in this study are hypothetical and were not directly measured.Click here for the journal source. Muyad J, Chauhan M, Hall L, et al. Glucagon-like peptide-1 receptor agonists and the risk of thyroid eye disease. Ophthalmic Plast Reconstr Surg. April 8, 2026. [Epub ahead of print]. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.